Cancer Research Meeting Calendar Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cahlin, C.
Right arrow Articles by Svanberg, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cahlin, C.
Right arrow Articles by Svanberg, E.
[Cancer Research 60, 5488-5493, October 1, 2000]
© 2000 American Association for Cancer Research

Experimental Therapeutics

Experimental Cancer Cachexia: The Role of Host-derived Cytokines Interleukin (IL)-6, IL-12, Interferon-{gamma}, and Tumor Necrosis Factor {alpha} Evaluated in Gene Knockout, Tumor-bearing Mice on C57 Bl Background and Eicosanoid-dependent Cachexia1

Christian Cahlin, A. Körner, H. Axelsson, Wenhua Wang, Kent Lundholm2 and Elisabeth Svanberg

Surgical Metabolic Research Laboratory and Lundberg Laboratory for Cancer Research, Department of Surgery, Sahlgrenska University Hospital, Göteborg University, S-413 45 Göteborg, Sweden


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
MCG 101 tumors were implanted sc. on wild-type C57 Bl and gene knockout mice to evaluate the role of host-produced cytokines [interleukin (IL)-6, IL-12, IFN{gamma}, tumor necrosis factor (TNF) receptor 1, and TNF receptor 2] to explain local tumor growth, anorexia, and carcass weight loss in a well-defined model with experimental cachexia. Indomethacin was provided in the drinking water to explore interactions between host and tumor-derived prostaglandins and proinflammatory cytokines for tumor growth. Wild-type tumor-bearing mice developed cachexia because of rapid tumor growth, which were both attenuated in IL-6 gene knockouts. Similar findings were observed after provision of anti-IL-6 to wild-type tumor-bearing mice. Alterations in food intake were not directly related to systemic IL-6 but rather secondarily to IL-6-dependent tumor growth. The absence of host-derived IL-12, IFN-{gamma}, or the TNF receptor 1 or receptor 2 gene did not attenuate tumor growth or improve subsequent cachexia. Thus, carcass weight loss was not improved by the omission of host cytokine (TNF-{alpha}, IL-12, or IFN-{gamma}) except for IL-6. Systemic indomethacin provision decreased plasma prostaglandin E2 in five of six groups of gene knockout tumor-bearing mice, which was associated with improved carcass weight in these groups. Indomethacin seemed to improve food intake to a similar extent in both wild-type and gene knockouts, which agree with the speculation that eicosanoids are more important to explain anorexia than host cytokines. Our results demonstrate that host- and tumor-derived cytokines and prostaglandins interact with tumor growth and promote cachexia in a more complex fashion than usually presented based on previous information in studies on either anti-cytokine experiments in vivo or on gene knockouts with respect to a "single cytokine model." Overall, host cytokines were quantitatively less important than tumor-derived cytokines to explain net tumor growth, which indirectly explains subsequent cachexia and anorexia.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
It is well established that proinflammatory cytokines are important to induce and promote development of experimental cancer cachexia (1 , 2) , although a corresponding role has not been confirmed in clinical studies (3 , 4) except for a potential role of IL-63 (5 , 6) . A quantitative discrepancy in effects on host metabolism and tumor growth among species may be manifold, but it cannot be excluded that prolonged artificial transplantation of tumors on inbred mice and rats would select tumor clones with a particular dependency for certain growth factors and cytokines. Accordingly, it has been observed repeatedly that monospecific neutralizing antibodies to certain cytokines improve anorexia, attenuate cachexia, and reduce tumor growth in tumor-bearing mice (7, 8, 9, 10, 11) . Such experiments with whole-body provision of neutralizing antibodies imply that several cytokines are quantitatively important to explain cachexia. It is, however, unclear to what extent large-sized antibodies, with limited tissue penetration, can effectively extinguish paracrine-acting cytokines for integrated organ functions, such as the hepatic acute phase response, central nervous system-related anorexia and sympathetic/parasympathetic circulatory alterations. Also, systemic provision of antibodies do not distinguish between effects from host versus tumor-produced cytokines. The availability of gene knockout mice bearing implanted tumors may therefore improve the possibility to evaluate the role of host versus tumor-derived cytokines for tumor progression (12, 13, 14) . The aim of the present study was therefore to evaluate to what extent host-derived cytokines of IL-6, IL-12, IFN-{gamma}, and TNF-{alpha} contribute to progressive cachexia in MCG 101-bearing mice on a C57 Bl genetic background and eicosanoid-dependent cachexia.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Animals and Experimental Design.
Mice with C57 Bl genetic background (18–22 g) were used in all experiments. The animals were housed prior to experimentation in a temperature-controlled room with a diurnal 12-h light cycle and provided with tap water and standard rodent chow ad libitum (B & K Universal, Stockholm, Sweden) for 2 weeks. The animals were then transferred to plastic cages with screen floors that permitted collection and quantification of spilled food. Under anesthesia with i.p. injection of 0.10 ml from a 1-ml stock solution of 0.4 ml of ketamine (100 µg/g; Parke-Davis), 0.05 ml xylozin (5 µg/g), and 0.55 ml saline, 3 mm3 of viable methylcholantrene-induced sarcoma (MCG 101) was implanted s.c. on each side of the midline. MCG 101 is a nonmetastasizing, undifferentiated, epithelial-like solid tumor that has been extensively used in our laboratory for study of cancer cachexia, and it has been grown continuously in vivo since 1975 (15) . The tumors grow locally with a reproducible growth pattern when implanted s.c. The animals die because of cancer cachexia 12–15 days after implantation (16, 17, 18) . The tumor produces IL-1{alpha}, IL-1ß, TNF-{alpha}, and IL-6 (8 , 19) but not IFN-{gamma} and IL-12.4 Prostaglandins, particularly PGE2, is also produced both in vitro and in vivo, leading to elevated host plasma concentrations (20 , 21) . Cyclooxygenase inhibition by indomethacin, which normalizes systemic levels of PGE2, has been reported to improve nutritional state and food intake, reduce tumor growth, and prolong survival in wild-type C57 Bl mice (22) .

Mice with genetic knockout of IL-6 (23 , 24) were provided by Professor Manfred Kopf (Basel Institute for Immunology, Basel, Switzerland) and Professor Andreij Tarkowskij (Department of Immunology, Göteborg University, Göteborg, Sweden); IL-12 (Roche, Nutley, NJ), IFN-{gamma} (Jackson Laboratories, Bar Harbor, ME), and TNF R1 and TNF R2 (The Jackson Laboratory, Bar Harbor, ME) were used in parallel to wild-type C57 Bl mice from Bomholts Gård (Ry, Denmark).

Anti-IL-6 (kindly obtained by Professor L. L. Moldawer, Department of Surgery, University of Florida, Gainesville, FL) was provided as i.p. injections (300 µg every third day). This experiment was performed to follow up on previous experiments with anti-IL-1 and TNF-{alpha} (7 , 21) . The hybridoma-grown monoclonal antibody, directed against murine IL-6, completely blocked the SAP, serum amyloid A protein, and orosomucoid response in abscess models (25) . Preimmune sera (IgG; Sigma Chemical Co., St. Louis, MO) served as control. Indomethacin (5 mg/ml; Dumex) was provided in the drinking water at a final concentration of 6.5 µg/l. Experiments with indomethacin were performed to evaluate whether cyclooxygenase-related tumor growth inhibition involves host cytokines. Murine IL-12 (0.2 µg/day i.p.) was obtained from Labkemi (Västra Frölunda, Sweden). These experiments were performed to demonstrate the paradox of attenuated tumor growth and improved nutritional state in combination, despite increased plasma PGE2 and IL-6 (Table 3)Citation . Suramin (Calbiochem), a functional IL-6 receptor antagonist, was provided on days 2, 5, and 8 i.p. at 100 µg/g, which has been demonstrated to decrease IL-6-related weight loss in colon 26-bearing mice (26) .


View this table:
[in this window]
[in a new window]

  		Table 3 Effect of IL-12 treatment (1 µg/day, i.p.) on tumor weight, carcass weight change, plasma PGE2, and IL-6 concentrations in wild-type (+/+) and gene knockout (-/-) tumor-bearing mice 12 days after tumor implantation

 
Food intake and body weight were measured daily as described (22 , 24 , 27) . The animals were killed by cervical dislocation 10–12 days after tumor implantation. Blood was drawn into heparinized syringes and frozen until analyses. The tumors were extirpated, weighed, and dried. Body carcass weight was registered, and body composition was evaluated by lipid extraction and drying to constant weight as described previously (28) . Alterations in carcass weight are presented as carcass weight changes during tumor progression, because presently used batches of gene knockout mice and corresponding controls had a comparatively large variation in pre-experimental body weight.

Biochemical Analyses.
Indomethacin (final concentration, 10 µg/ml) was added to blood samples to prevent further breakdown of arachidonic acid in analyses of serum concentrations of prostaglandins. The serum was acidified and ethanol precipitated after centrifugation. PGE2 was extracted on AmPrep C18 mini columns (Amersham; RPN 1900) and quantified by RIA (Amersham) within 6 days. SAP was quantified by rocket immunoelectrophoresis as described (29) . Plasma IL-6 was measured by ELISA from Amersham (Buckinghamshire, United Kingdom).

Statistics.
Results are expressed as mean ± SE. Multiple group comparisons were performed by one-way ANOVA. Time course changes between study and control mice were evaluated by ANOVA for repeated measures. P < 0.05 was considered statistically significant. Scheffe-F test was used post hoc.

Primarily, tumor-bearing gene knockout mice were compared statistically to randomly selected wild-type tumor-bearing mice (Tables 1Citation 2Citation 3)Citation . For evaluation of anorexia, statistical computations were also performed on pooled groups of wild-type and gene knockouts (Fig. 3)Citation to increase the number of statistical degrees of freedom in measurements on food intake, where each cage contained the average intake of five animals. Thus, the total number of cages was 33 containing 143 mice. The biological justification of this procedure was based on the assumption that any loss of a host cytokine gene could imply a functional deficiency compared with the situation with all genes being intact.


View this table:
[in this window]
[in a new window]

  		Table 1 Tumor and carcass weight changes in relation to plasma PGE2 and IL-6 concentrations in wild-type (+/+) and gene knockout (-/-) tumor-bearing mice 12 days after tumor implantation

 

View this table:
[in this window]
[in a new window]

  		Table 2 Effect of indomethacin treatment on tumor weight, carcass weight change, plasma PGE2, and IL-6 concentrations in wild-type and gene knockout (-/-) tumor-bearing mice 12 days after tumor implantation

 


View larger version (39K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Food intake of wild-type tumor-bearing mice (wt tb, df = 9; 23 mice in each group) compared with tumor-bearing knockouts with (ko tb indo, df = 12; 60 mice) and without (ko tb, df = 12; 60 mice) indomethacin treatment as described in "Materials and Methods." The decline in food intake was statistically significant over time in all three groups (P < 0.01). Indomethacin-treated knockout tumor-bearing mice had significantly improved food intake compared with the other groups evaluated by factorial ANOVA for repeated measures (P < 0.04). Statistical degrees of freedom (df) within parentheses refer to number of metabolic cages where food intake was registered as the mean intake/mouse in groups of five animals/cage. Bars, SE.

 
The experimental protocol was approved by the Committee for Animal Ethics at the University of Göteborg, Sweden.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Tumor Growth.
Tumor growth was similar among different cohorts of wild-type mice when compared, although our experiments on various groups were carried out at different occasions. All of these control mice were pooled to represent one reference group in comparison to the smaller groups with gene knockout mice (Table 1)Citation . Tumor growth on IL-6 knockout mice (IL-6 -/-) displayed a significant reduction (48 ± 14%; P < 0.01), whereas tumor growth was not significantly changed on IL-12 (-/-), IFN-{gamma} (-/-), TNF R1(-/-), and TNF R2 (-/-) knockout mice compared with wild-type controls.

Provision of neutralizing antibodies toward IL-6 in wild-type tumor-bearing mice reduced tumor growth (40 ± 10%; P < 0.01) by an order of magnitude observed for tumor growth in gene knockout IL-6 (-/-) tumor-bearing mice. This growth inhibition was associated with reduction in the hepatic acute phase response demonstrated by reduced plasma levels of SAP protein from 109 ± 24 to 27 ± 4 ng/ml (P < 0.01) and plasma IL-6 close to detection limits. However, suramin, an assumed functional IL-6 receptor antagonist, had no effect to reduce tumor growth in wild-type tumor-bearing mice (results not shown).

Indomethacin reduced tumor growth by 32 ± 8% (P < 0.03) in wild-type C57 Bl mice. This effect was also observed in IL-12 (-/-) knockout mice (36 ± 9%; P < 0.05), whereas indomethacin had no clear cut effect to reduce tumor growth in groups of IL-6 (-/-), IFN-{gamma} (-/-), TNF R1 (-/-), or TNF R2 (-/-) deficient mice (Table 2)Citation .

Daily i.p. provision of recombinant IL-12 to wild-type tumor-bearing mice reduced tumor growth by 75 ± 13% (P < 0.001), whereas the same provision of IL-12 to IFN-{gamma} (-/-) knockouts had no effect on tumor growth (Table 3)Citation .

Carcass Weight Change.
Tumor growth in wild-type mice caused reduction of carcass weight, which was significantly attenuated in IL-6 (-/-) knockouts, in agreement with the effects observed in wild type mice when provided i.p. with antibodies toward IL-6 (not shown). However, carcass weight change in IL-12 (-/-) and IFN-{gamma} (-/-) gene knockout mice were not significantly changed compared with wild type. By contrast, carcass weight losses in TNF R1 or R2 (-/-) mice were even significantly more pronounced compared with either wild-type mice or to the other groups of gene knockout mice (Table 1)Citation . Indomethacin attenuated carcass weight loss in IFN-{gamma} (-/-), TNF R1, and TNF R2 (-/-) tumor-bearing mice and even increased carcass weight in IL-6 (-/-) and IL-12 (-/-) tumor-bearing gene knockout mice (Table 2)Citation . IL-12 treatment to wild-type tumor-bearing mice was also associated with significantly increased carcass weight, whereas this effect was entirely absent after IL-12 treatment of IFN-{gamma} (-/-) tumor-bearing mice (Table 3)Citation .

Food Intake.
Food intake was stable in nontumor-bearing wild-type and knockout mice during a 2-week period, indicating steady-state conditions in our experimental environment (not shown). Progressive tumor growth was associated with the appearance of anorexia in all groups of tumor-bearing animals, i.e., in both wild-type and gene knockout mice (P < 0.001). Indomethacin improved food intake in wild-type tumor-bearing mice when evaluated over the entire experimental period (days 1–10; P < 0.01; Fig. 1Citation ). Evaluations of food intake between study and control mice were limited to the period between day 6 and 10 after tumor implantation to primarily focus on the tumor-induced anorexia, because days 4–6 were the period when food intake was restituted in all animal groups subsequent to the initial anorexia associated with anesthesia and tumor implantation. All groups of tumor-bearing knockouts had statistically significant anorexia when compared with wild-type non-tumor-bearing controls (P < 0.01), but no significant changes were observed between wild-type and gene knockout mice (not shown). i.p. provision of neutralizing antibodies toward IL-6 in wild-type tumor-bearing mice did not improve anorexia (not shown), which was also true for indomethacin treatment of IL-6 knockout mice (Fig. 2)Citation . However, indomethacin improved food intake when evaluated in pooled groups of knockout tumor-bearing mice by the same magnitude as observed for indomethacin in wild-type tumor-bearing mice (Fig. 3)Citation .



View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Time course changes of food intake in wild-type tumor-bearing mice with and without indomethacin treatment from days 1–10 as described in "Materials and Methods." The difference over time in food intake was statistically different between the two groups evaluated by ANOVA for repeated measures (P < 0.01). Bars, SE.

 


View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Food intake in tumor-bearing IL-6 (-/-) knockout mice with (n = 17) and without (n = 17) indomethacin treatment from day 1 as described in "Materials and Methods." The decline in food intake was statistically significant in both groups (P < 0.01), without any difference between the two groups. Bars, SE.

 
Plasma PGE2 and IL-6.
Plasma PGE2 levels were 65 ± 18pg/ml in C57 Bl wild-type non-tumor-bearing mice. These levels were increased to 1574 ± 309 pg/ml in wild-type tumor-bearing mice (Table 1)Citation , whereas indomethacin treatment reduced PGE2 concentrations to 404 ± 48 pg/ml in wild-type tumor-bearing mice (Table 2)Citation . Tumor-bearing IFN-{gamma} (-/-) mice had significantly reduced plasma PGE2 levels comparable with wild-type tumor-bearing mice, whereas all other tumor-bearing gene knockout mice showed plasma PGE2 concentrations that were not significantly different from wild-type concentrations. IL-12 provision to wild-type tumor-bearing mice increased plasma PGE2 8-fold in wild-type mice (P < 0.01) but not in IFN-{gamma} (-/-) tumor-bearing mice (Table 3)Citation .

IL-12 provision to wild-type tumor-bearing mice also increased plasma IL-6 3-fold (P < 0.005) but had no stimulatory effect on plasma IL-6 in IFN-{gamma} (-/-) knockout mice (Table 3)Citation . IL-12 provision to wild-type mice reduced plasma SAP by 50 ± 8% (not shown), despite elevation of plasma IL-6 in these mice (Table 3)Citation .

Measurable concentrations of plasma IL-6 occurred in IL-6 (-/-) knockouts, which represents tumor-derived IL-6 (Table 1)Citation , because IL-6 knockouts lack IL-6 mRNA expression in host tissues, even in response to lipopolysaccharide stimulation (24) . Indomethacin treatment did not reduce tumor-derived IL-6 in IL-6 (-/-) knockouts further but increased plasma IL-6 in wild-type tumor-bearing mice (Table 2)Citation , which confirms our previous findings on circulatory bioactive hepatocyte growth factor/IL-6 activity (19) .


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The aim of this study was to estimate the quantitative role of host-derived cytokines (IL-6, IL-12, IFN-{gamma}, and TFN-{alpha}) to explain progressive cachexia associated with tumor growth in a defined mouse model with eicosanoid-dependent cachexia. Possible mechanisms behind cancer cachexia have earlier been explored using neutralizing monospecific antibodies toward cytokines (7 , 8 , 10 , 11) . This is a straight-forward technique but with some theoretical limitations. Drawbacks may be time- and distribution-related restrictions for penetration of large antibodies throughout tissue compartments at the cellular level, but paradoxical effects may also occur (25) . Therefore, we considered it valuable to extend previous observations on tumor growth and cachexia in a well-characterized tumor model on gene knockout mice as applied by others (12 , 14) to specify potential contributions of host-derived cytokines versus some tumor-derived cytokines. For this purpose, we were restricted to the use of gene knockout mice with a genetic background similar to that of a well-characterized tumor with the production of IL-6, and TNF-{alpha}, whereas IFN-{gamma} and IL-12 were only produced in host tissues. The MCG 101 tumor kills the host because of negative energy balance by inducing anorexia, carcass weight loss, and altered body composition without limiting survival because of metastatic spread (15, 16, 17, 18 , 20 , 22 , 27 , 28 , 30) .Our present results demonstrate that development of experimental cachexia seems to be more complex than emphasized previously in reports on the role of anti-IL-1, anti-TNF-{alpha}, anti-IL-6, and anti-IFN-{gamma} to explain cachexia (1 , 7) experiments that focused on only one cytokine at a time (1 , 13 , 14) .

In agreement with previous results, i.p. provision of monospecific antibodies to IL-6 in wild-type tumor-bearing mice caused a decrease in systemic inflammation, demonstrated by lower plasma concentrations of SAP and IL-6 associated with decreased tumor growth but unexpectedly without improved food intake (14) . Thus, anti-IL-6 had to some extent similar effects as anti-IL-1 and anti-TNF-{alpha} (9 , 10 , 31) . Accordingly, tumor growth in IL-6 (-/-) knockout mice was associated with a corresponding decline in tumor growth and improved carcass weight but without direct effects on food intake. Thus, IL-6 experiments imply that antibodies neutralize plasma IL-6, originating from either tumor or host tissues attenuating tumor growth, which secondarily leads to improved nutritional state. IL-6 continued to appear in the circulation of IL-6 (-/-) knockouts, because the tumor cells were IL-6 (+/+) competent, whereas the host completely lacks IL-6 expression, even in response to bacterial antigens (24) . Thus, our results suggest that IL-6, derived from both tumor and host tissues, is a significant tumor growth factor with similar effects as IL-1 and TNF-{alpha} on MCG 101 cells (8) . Therefore, it seems tempting to conclude that increasing plasma IL-6 would deteriorate appetite and nutritional state (2 , 14) , but our results did not reveal improved anorexia in IL-6 knockout mice or in anti-IL-6-treated tumor bearers, findings that agree with prolonged anorexia following sepsis in IL-6 knockout mice (32) , pronounced anorexia in IL-6-deficient mice (33) , as well as a lack of anorexia after intracerebroventricular infusions of IL-6 (34) . In addition, IL-6 content in brain areas of importance for food regulation did not support IL-6 as a directly acting central nervous cytokine in MCG 101-bearing mice.4 Also, our experiments with i.p. provision of recombinant IL-12 to wild-type tumor-bearing mice caused a dramatic reduction in tumor growth and improved nutritional state and food intake as observed by others (35 , 36) , despite a pronounced increase in both plasma IL-6 and PGE2. These seemingly discrepant results may indicate that IL-6 regulation of tumor growth is more predictive for outcome of cachexia than even substantially elevated plasma levels of cytokines (IL-6) and PGE2. Also, reduced tumor growth did override the effect of increased plasma IL-6 on circulating acute phase reactants in IL-12-treated tumor bearers, which was unexpected in the light of previous conclusions on the role of cytokine regulation of acute phase reactants (33 , 34) . Similiarly, reversion of cachexia, despite high plasma concentrations of IL-6, has been reported by others after systemic elevation of IL-10 in colon 26-bearing mice (37) . Thus, IL-6 seems to be necessary for tumor induction of cachexia but not sufficient (38) , as concluded after lipopolysaccharide induction of cachexia in IL-6-deficient, non-tumor-bearing mice (32) .

In contrast to our previous findings that provision of anti-TNF-{alpha} attenuated cachexia (7 , 8) , we could not demonstrate that the lack of host receptors of either TNF R1 or R2 had any positive effect on tumor growth, carcass weight, or food intake. These discrepancies compared with previous results may either indicate that subtypes of TNF receptors can substitute for each other, or that TNF binding to host receptors is of less importance. Therefore, TNF and IL-1 receptors on tumor cells must be more important than corresponding TNF receptors in host tissues, a conclusion in agreement with our previous report that both TNF-{alpha} and IL-1 represent growth factors for MCG 101 cells (8) , now also demonstrated for IL-6. Thus, our present and previous results suggest that tumor production of cytokines is more important to indirectly explain cachexia than a concept with tumor-induced production of host cytokines (TNF-{alpha}, IL-12, and IFN-{gamma}), whereas IL-6 seems to have a dual role, as also supported by clinical studies (5 , 6) . Thus, we may either imply additional effector molecules in host tissues (39) or simply conclude that substrate flows among tumor and host compartments remain a major factor behind experimental cachexia (40, 41, 42) . This old and conservative concept agrees with our earlier observations that glucose consumption in MCG 101 tumors explains the major part of carcass weight loss in combination with anorexia, and death occurs when tumor glucose consumption exceeds the capacity for liver gluconeogenesis (17) .

Our present results demonstrate that the lack of either IFN-{gamma} or IL-12 genes in host tissues did not influence tumor growth and carcass weight, despite the fact that provision of exogenous IL-12 decreased tumor growth, a phenomenon again suggesting that host production of these cytokines is of less importance for tumor growth and related cachexia. The effect by exogenous IL-12 on tumor growth was completely absent in IFN-{gamma} (-/-) knockout mice, suggesting that IFN-{gamma} was the effector molecule as described by others (35) . Confusingly, published results suggest IFN-{gamma} as a potent trigger for development of experimental cancer cachexia based on either experiments with neutralizing antibodies toward IFN-{gamma} or in experiments with excess production of IFN-{gamma} in vivo by engineered tumor cells (11 , 43) , but clinical studies do not support such a concept (5) . Although the release of IFN from either tumor or host cells after IL-12 provision was not quantified, it is likely that inhibition of tumor growth by IL-12 was explained by increased host production of IFN-{gamma} in response to IL-12 (44 , 45) , because tumor cells were IFN-{gamma} gene competent also in host gene knockout experiments. All of these results support the conclusion that host production of IFN-{gamma} or IL-12 was not involved in the systemic development of cancer cachexia in this model, which does not exclude the apparent observation that high concentration of IL-12 and IFN-{gamma} can trigger reactions that restrict tumor growth, which secondarily improves cachexia. Therefore, the most simple explanation to our present and previous results is that a number of cytokines control local tumor growth, which is the primary and overall determinant of experimental cancer cachexia.

We have repeatedly reported that provision of indomethacin to MCG-bearing mice retards tumor growth, as confirmed in the present study (20 , 22) . This effect may be regarded as related to either host production of cytokines or to host and tumor production of prostaglandins, particularly PGE2 (21 , 46) . Tumor inhibition by indomethacin in the MCG 101 model is not related to any particular vascular bed or organ (20) , but we have repeatedly assumed that it is partly dependent on decreased host production of systemic proinflammatory cytokines. Our present results indicate that indomethacin clearly retarded tumor growth in wild-type tumor-bearing mice but had less clear cut effects on tumor growth in gene knockout mice. However, the improved effect by indomethacin on carcass weight was clear cut in all groups of host gene knockout mice, directionally correlated to declines in PGE2 but not to IL-6 (Table 2)Citation . Thus, we are left with the impression that indomethacin improves carcass weight by either decreased tumor or systemic production of PGE2, which however led to minor and variable effects on tumor growth. This conclusion agrees with our previous observations in survival experiments with indomethacin, where treatment of wild-type mice allows tumor-bearing mice to die with larger tumors but less depleted carcasses compared with tumor bearers without indomethacin. Similar observations have also been made in cancer patients (47) . The observations in the present study also agree with recent observations in our laboratory that brain cytokines do not explain tumor-induced anorexia, whereas prostaglandins (PGE2) may do so.4 If so, it may explain why food intake was significantly improved in pooled groups of indomethacin-treated knockouts (Fig. 3)Citation .

In conclusion, present experiments in gene knockout tumor-bearing mice demonstrate that evaluations behind systemic effects of tumor growth may be extended when performed in combined experiments with neutralizing antibodies and gene knockout mice, because tumor cells were wild-type and host cells were knockout for cytokines that control tumor growth. This study confirms that host production of IL-6 contributes to the development of cachexia, whereas host production of TNF-{alpha}, IL-12, and IFN-{gamma} was insignificant. Therefore, a role of TNF-{alpha} in host wasting is related to tumor production of TNF, whereas neither host nor tumor production of IL-12 and IFN-{gamma} explains cachexia. However, large amounts or high tissue concentrations of IL-12 and IFN-{gamma} can obviously override the cachectic effects of both IL-6 and PGE2 by restriction of tumor growth. Thus, tumor mass is the outstanding predictor of cachexia. This conclusion has support in older observations that tumor-bearing mice die when tumor energy consumption exceeds counter regulatory mechanisms such as gluconeogenesis (17) , and that s.c. expansion of an inert mass can induce similar metabolic alterations in such animals as observed in tumor bearers (42) . How indomethacin improves the metabolic balance between a growing tumor and its host remains to be determined.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by Grants 2014-B98-12XAC and 01PAA from the Swedish Cancer Society, Grants K99-72X-08712-11A and 13159 from the Medical Research Council, and grants from the Tore Nilsson Foundation, Assar Gabrielsson Foundation (AB Volvo), Jubileumskliniken Foundation, IngaBritt and Arne Lundberg Research Foundation, Axel and Margaret Axson Johnson Foundation, Knut and Alice Wallenberg Foundation, Swedish and Göteborg Medical Societies, and the Medical Faculty, University of Göteborg. Back

2 To whom requests for reprints should be addressed, at Department of Surgery, Sahlgrenska University Hospital, Göteborg University, S-413 45 Göteborg, Sweden. Back

3 The abbreviations used are: IL, interleukin; TNF, tumor necrosis factor; R1, receptor 1; R2, receptor 2; PGE2, prostaglandin E2; SAP, serum amyloid P. Back

4 Unpublished observations. Back

Received 12/28/99. Accepted 4/28/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Moldawer L. L., Georgieff M., Lundholm K. Interleukin 1, tumour necrosis factor-{alpha} (cachectin) and the pathogenesis of cancer cachexia. Clin. Physiol., 7: 263-274, 1987.[Medline]
  2. Argiles J. M., Lopez-Soriano F. J. The role of cytokines in cancer cachexia. Med. Res. Rev., 19: 223-248, 1999.[Medline]
  3. Moldawer L. L., Drott C., Lundholm K. Monocytic production and plasma bioactivities of interleukin-1 and tumour necrosis factor in human cancer. Eur. J. Clin. Investig., 18: 486-492, 1988.[Medline]
  4. Espat N. J., Moldawer L. L., Copeland E. M., III. Cytokine-mediated alterations in host metabolism prevent nutritional repletion in cachectic cancer patients. J. Surg. Oncol., 58: 77-82, 1995.[Medline]
  5. Martin F., Santolaria F., Batista N., Milena A., Gonzalez-Reimers E., Brito M. J., Oramas J. Cytokine levels (IL-6 and IFN-{gamma}), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine, 11: 80-86, 1999.[Medline]
  6. Emilie D., Wijdenes J., Gisselbrecht C., Jarrousse B., Billaud E., Blay J. Y., Gabarre J., Gaillard J. P., Brochier J., Raphael M. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood, 84: 2472-2479, 1994.[Abstract/Free Full Text]
  7. Sherry B. A., Gelin J., Fong Y., Marano M., Wei H., Cerami A., Lowry S. F., Lundholm K. G., Moldawer L. L. Anticachectin/tumor necrosis factor-{alpha} antibodies attenuate development of cachexia in tumor models. FASEB J., 3: 1956-1962, 1989.[Abstract]
  8. Gelin J., Moldawer L. L., Lönnroth C., Sherry B., Chizzonite R., Lundholm K. Role of endogenous tumor necrosis factor {alpha} and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res., 51: 415-421, 1991.[Abstract/Free Full Text]
  9. Strassmann G., Fong M., Kenney J. S., Jacob C. O. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Investig., 89: 1681-1684, 1992.
  10. Strassmann G., Masui Y., Chizzonite R., Fong M. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J. Immunol., 150: 2341-2345, 1993.[Abstract]
  11. Matthys P., Heremans H., Opdenakker G., Billiau A. Anti-interferon-{gamma} antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur. J. Cancer, 27: 182-187, 1991.
  12. Lopez-Soriano J., Llovera M., Carbo N., Garcia-Martinez C., Lopez-Soriano F. J., Argiles J. M. Lipid metabolism in tumour-bearing mice: studies with knockout mice for tumour necrosis factor receptor 1 protein. Mol. Cell. Endocrinol., 132: 93-99, 1997.[Medline]
  13. Llovera M., Garcia-Martinez C., Lopez-Soriano J., Agell N., Lopez-Soriano F. J., Garcia I., Argiles J. M. Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett., 130: 19-27, 1998.[Medline]
  14. Molotkov A., Satoh M., Tohyama C. Tumor growth and food intake in interleukin-6 gene knockout mice. Cancer Lett., 132: 187-192, 1998.[Medline]
  15. Lundholm K., Edstrom S., Ekman L., Karlberg I., Bylund A. C., Schersten T. A comparative study of the influence of malignant tumor on host metabolism in mice and man: evaluation of an experimental model. Cancer (Phila.), 42: 453-461, 1978.[Medline]
  16. Karlberg I., Edstrom S., Ekman L., Johansson S., Schersten T., Lundholm K. Metabolic host reaction in response to the proliferation of nonmalignant cells versus malignant cells in vivo. Cancer Res., 41: 4154-4161, 1981.[Abstract/Free Full Text]
  17. Svaninger G., Gelin J., Lundholm K. The cause of death in non-metastasizing sarcoma-bearing mice. A study with relevance for tumor treatment experiments in mice. Eur. J. Cancer Clin. Oncol., 25: 1295-1302, 1989.
  18. Lindmark L., Edstrom S., Ekman L., Karlberg I., Lundholm K. Energy metabolism in nongrowing mice with sarcoma. Cancer Res., 43: 3649-3654, 1983.[Abstract/Free Full Text]
  19. Gelin J., Moldawer L. L., Lönnroth C., deMan P., Svanborg-Eden C., Lowry S. F., Lundholm K. G. Appearance of hybridoma growth factor/interleukin-6 in the serum of mice bearing a methylcholanthrene-induced sarcoma. Biochem. Biophys. Res. Commun., 157: 575-579, 1988.[Medline]
  20. Lönnroth C., Svaninger G., Gelin J., Cahlin C., Iresjö B-M., Cvetkovska E., Edström S., Andersson M., Svanberg E., Lundholm K. Effects related to indomethacin prolonged survival and decreased tumor growth in a mouse tumor model with cytokine dependent cancer cachexia. Int. J. Oncol., 7: 1405-1413, 1995.
  21. Cahlin C., Gelin J., Delbro D., Lönnroth C., Doi C., Lundholm K. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res., 60: 1742-1749, 2000.[Abstract/Free Full Text]
  22. Gelin J., Andersson C., Lundholm K. Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res., 51: 880-885, 1991.[Abstract/Free Full Text]
  23. Kopf M., Le Gros G., Coyle A. J., Kosco-Vilbois M., Brombacher F. Immune responses of IL-4, IL-5, IL-6 deficient mice. Immunol. Rev., 148: 45-69, 1995.[Medline]
  24. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., Zinkernagel R., Bluethmann H., Kohler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (Lond.), 368: 339-342, 1994.[Medline]
  25. May L. T., Neta R., Moldawer L. L., Kenney J. S., Patel K., Sehgal P. B. Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J. Immunol., 151: 3225-3236, 1993.[Abstract]
  26. Walz T. M., Abdiu A., Wingren S., Smeds S., Larsson S-E., Wasteson A. Suramin inhibits growth of human osteosarcoma xenografts in nude mice. Cancer Res., 51: 3585-3589, 1991.[Abstract/Free Full Text]
  27. Lundholm K., Karlberg I., Ekman L., Edstrom S., Schersten T. Evaluation of anorexia as the cause of altered protein synthesis in skeletal muscles from nongrowing mice with sarcoma. Cancer Res., 41: 1989-1996, 1981.[Abstract/Free Full Text]
  28. Eden E., Lindmark L., Karlberg I., Lundholm K. Role of whole-body lipids and nitrogen as limiting factors for survival in tumor-bearing mice with anorexia and cachexia. Cancer Res., 43: 3707-3711, 1983.[Abstract/Free Full Text]
  29. Ternell M., Moldawer L. L., Lönnroth C., Gelin J., Lundholm K. G. Plasma protein synthesis in experimental cancer compared to paraneoplastic conditions, including monokine administration. Cancer Res., 47: 5825-5830, 1987.[Abstract/Free Full Text]
  30. Svaninger G., Isaksson O., Lundholm K. Growth hormone and experimental cancer cachexia. J. Natl. Cancer Inst., 79: 1359-1365, 1987.
  31. Strassmann G., Fong M., Freter C. E., Windsor S., D’Alessandro F., Nordan R. P. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J. Clin. Investig., 92: 2152-2159, 1993.
  32. Fattori E., Cappelletti M., Costa P., Sellitto C., Cantoni L., Carelli M., Faggioni R., Fantuzzi G., Ghezzi P., Poli V. Defective inflammatory response in interleukin 6-deficient mice. J. Exp. Med., 180: 1243-1250, 1994.[Abstract/Free Full Text]
  33. Josephs M. D., Solorzano C. C., Taylor M., Rosenberg J. J., Topping D., Abouhamze A., Mackay S. L., Hirsch E., Hirsh D., Labow M., Moldawer L. L. Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-1ra. Am. J. Physiol. Regul. Integr. Comp. Physiol., 278: R824-30 2000.[Abstract/Free Full Text]
  34. Hill A. G., Jacobson L., Gonzalez J., Rounds J., Majzoub J. A., Wilmore D. W. Chronic central nervous system exposure to interleukin-1ß causes catabolism in the rat. Am. J. Physiol., 271: R1142-R1148, 1996.[Abstract/Free Full Text]
  35. Shurin M. R., Esche C., Peron J. M., Lotze M. T. Antitumor activities of IL-12 and mechanisms of action. Chem. Immunol., 68: 153-174, 1997.[Medline]
  36. Fujiwara H., Clark S. C., Hamaoka T. Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Ann. NY Acad. Sci., 795: 294-309, 1996.[Medline]
  37. Fujiki F., Mukaida N., Hirose K., Ishida H., Harada A., Ohno S., Bluethmann H., Kawakami M., Akiyama M., Sone S., Matsushima K. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res., 57: 94-99, 1997.[Abstract/Free Full Text]
  38. Yasumoto K., Mukaida N., Harada A., Kuno K., Akiyama M., Nakashima E., Fujioka N., Mai M., Kasahara T., Fujimoto-Ouchi K., Mori K., Tanaka Y., Matsushima K. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res., 55: 921-927, 1995.[Abstract/Free Full Text]
  39. Todorov P., Cariuk P., McDevitt T., Coles B., Fearon K., Tisdale M. Characterization of a cancer cachectic factor. Nature (Lond.), 379: 739-742, 1996.[Medline]
  40. Waterhouse C. How tumors affect host metabolism. Ann. NY Acad. Sci., 230: 86-93, 1974.[Medline]
  41. Strain A. J. Cancer cachexia in man: a review. Investig. Cell Pathol., 2: 181-193, 1979.
  42. Morrison S. D., Moley J. F., Norton J. A. Contribution of inert mass to experimental cancer cachexia in rats. J. Natl. Cancer Inst., 73: 991-998, 1984.
  43. Matthys P., Dijkmans R., Proost P., Van Damme J., Heremans H., Sobis H., Billiau A. Severe cachexia in mice inoculated with interferon-{gamma}-producing tumor cells. Int. J. Cancer, 49: 77-82, 1991.[Medline]
  44. Osaki T., Peron J. M., Cai Q., Okamura H., Robbins P. D., Kurimoto M., Lotze M. T., Tahara H. IFN-{gamma}-inducing factor/IL-18 administration mediates IFN-{gamma}- and IL-12-independent antitumor effects. J. Immunol., 160: 1742-1749, 1998.[Abstract/Free Full Text]
  45. Okamura H., Kashiwamura S., Tsutsui H., Yoshimoto T., Nakanishi K. Regulation of interferon-{gamma} production by IL-12 and IL-18. Curr. Opin. Immunol., 10: 259-264, 1998.[Medline]
  46. Lönnroth, C., Andersson, M., Iresjö, B-M., Karlsson, L., and Lundholm, K. Indomethacin influences on telomerase activity in tumor-bearing mice and cells in vitro. Miami Nature Biotechnology Short Reports, Vol. 11, February 6–10, Oxford University Press, 1999.
  47. Lundholm, K., Gelin, J., Hyltander, A., Lönnroth, C., Sandstrom, R., and Svaninger, G. with support from Körner, U., Gülich, M., Kärrefors, I., Norli, B., Hafström, L. O., Kewenter, J., Olbe, L., and Lundell, L. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res., 54: 5602–5606, 1994.



This article has been cited by other articles:


Home page
 JPEN J Parenter Enteral NutrHome page
Y.-J. Nai, Z.-W. Jiang, Z.-M. Wang, N. Li, and J.-S. Li
Prevention of Cancer Cachexia by Pyrrolidine Dithiocarbamate (PDTC) in Colon 26 Tumor-Bearing Mice
JPEN J Parenter Enteral Nutr, January 1, 2007; 31(1): 18 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Biol Res NursHome page
L. J. Wood, L. M. Nail, N. A. Perrin, C. R. Elsea, A. Fischer, and B. J. Druker
The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production and Sickness Behavior-like Symptoms in a Mouse Model of Cancer Chemotherapy-Related Symptoms.
Biol Res Nurs, October 1, 2006; 8(2): 157 - 169.
[Abstract] [PDF]

Home page
 JCOHome page
K. C.H. Fearon, M. D. Barber, A. G. Moses, S. H. Ahmedzai, G. S. Taylor, M. J. Tisdale, and G. D. Murray
Double-Blind, Placebo-Controlled, Randomized Study of Eicosapentaenoic Acid Diester in Patients With Cancer Cachexia
J. Clin. Oncol., July 20, 2006; 24(21): 3401 - 3407.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
J. Y. McClintock and E. M. Wagner
Role of IL-6 in systemic angiogenesis of the lung
J Appl Physiol, September 1, 2005; 99(3): 861 - 866.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. E. Martignoni, P. Kunze, W. Hildebrandt, B. Kunzli, P. Berberat, T. Giese, O. Kloters, J. Hammer, M. W. Buchler, N. A. Giese, et al.
Role of Mononuclear Cells and Inflammatory Cytokines in Pancreatic Cancer-Related Cachexia
Clin. Cancer Res., August 15, 2005; 11(16): 5802 - 5808.
[Abstract] [Full Text] [PDF]

Home page
 Biol Res NursHome page
D. O. McCarthy
Rethinking Nutritional Support for Persons with Cancer Cachexia
Biol Res Nurs, July 1, 2003; 5(1): 3 - 17.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cahlin, C.
Right arrow Articles by Svanberg, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cahlin, C.
Right arrow Articles by Svanberg, E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online